Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases-Reference-Cited by-同舟云学术

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

Published:2006 Issue:2 Volume:208 Page:344-353
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Morelli Maria Pia,Cascone Tina,Troiani Teresa,Tuccillo Concetta,Bianco Roberto,Normanno Nicola,Romano Marco,Veneziani Bianca Maria,Fontanini Gabriella,Eckhardt S. Gail,De Pacido Sabino,Tortora Giampaolo,Ciardiello Fortunato

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference39 articles.

1. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

2. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents

3. Analysis of combined drug effects: a new look at a very old problem

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of Vaterite Nanoparticles for Controlled Delivery of Active Immunotherapeutic Proteins;Particle & Particle Systems Characterization;2024-03-12

2. Antitumor activity of the VEGFR inhibitor ZD6474 in human cancer cells resistant to anti-EGFR therapy;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

3. Advances and challenges in the treatment of esophageal cancer;Acta Pharmaceutica Sinica B;2021-11

4. Development of a new EGFR antibody antagonist which exhibits potential biological effects against laryngeal cancer;Annals of Translational Medicine;2021-06

5. Molecular Pathology of Lung Tumors;Pathology of Lung Disease;2021